Alejandro Marin-Lopez

Dr. Alejandro Marin-Lopez

Department of Internal medicine, Section of Infectious Diseases, School of Medicine, Yale University, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
YWyuchen wang
yuchen wang
LLLing Lin
Ling Lin
ZZZilei Zhang
Zilei Zhang
AMAlejandro Marin-Lopez
Alejandro Marin-Lopez
Zika virus (ZIKV), an emerging arthropod-borne flavivirus, was first isolated in Uganda in 1947 from monkeys and first detected in humans in Nigeria in 1952; it has been associated with a dramatic burden worldwide. Since then, interventions to reduce the burden of ZIKV infection have been mainly restricted to mosquito control, which in the end proved to be insufficient by itself. Hence, the situation prompted scientists to increase research on antivirals and vaccines against the virus. These efforts are still ongoing as the pathogenesis and immune evasion mechanisms of ZIKV have not yet been fully elucidated. Understanding the viral disease mechanism will provide a better landscape to develop prophylactic and therapeutic strategies against ZIKV. Currently, no specific vaccines or drugs have been approved for ZIKV. However, some are undergoing clinical trials. Notably, different platforms have been evaluated for the design of vaccines, including DNA, mRNA, viral vectors, virus-like particles (VLPs), inactivated virus, live attenuated virus, peptide and protein-based vaccines, passive immunizations by using monoclonal antibodies (MAbs), and vaccines that target vector-derived antigens. These vaccines have been shown to induce specific humoral and cellular immune responses and reduce viremia and viral RNA titers, both in vitro and in vivo. This review provides a comprehensive summary of current advancements in the development of vaccines against Zika virus.

1 March 2014 in Virus Research
Verified
Journal Article
Open access
ECEva Calvo-Pinilla
Eva Calvo-Pinilla
JCJavier Castillo-Olivares
Javier Castillo-Olivares
TJTamara Jabbar
Tamara Jabbar
JOJavier Ortego
Javier Ortego
FPFrancisco de la Poza
Francisco de la Poza
AMAlejandro Marin-Lopez
Alejandro Marin-Lopez
Bluetongue (BT) is a hemorrhagic disease of ruminants caused by bluetongue virus (BTV), the prototype member of the genus Orbivirus within the family Reoviridae and is transmitted via biting midges of the genus Culicoides. BTV can be found on all continents except Antarctica, and up to 26 immunologically distinct BTV serotypes have been identified. Live attenuated and inactivated BTV vaccines have been used over the years with different degrees of success. The multiple outbreaks of BTV in Mediterranean Europe in the last two decades and the incursion of BTV-8 in Northern Europe in 2008 has re-stimulated the interest to develop improved vaccination strategies against BTV. In particular, safer, cross-reactive, more efficacious vaccines with differential diagnostic capability have been pursued by multiple BTV research groups and vaccine manufacturers. A wide variety of recombinant BTV vaccine prototypes have been investigated, ranging from baculovirus-expressed sub-unit vaccines to the use of live viral vectors. This article gives a brief overview of all these modern approaches to develop vaccines against BTV including some recent unpublished data.

8 January 2019 in Viruses
Verified
Journal Article
Open access
PDF file
AMAlejandro Marin-Lopez
Alejandro Marin-Lopez
ECEva Calvo-Pinilla
Eva Calvo-Pinilla
SMSandra Moreno
Sandra Moreno
SUSergio Utrilla
Sergio Utrilla
ANAITOR NOGALES
AITOR NOGALES
JOJavier Ortego
Javier Ortego
Arboviruses are arthropod-borne viruses that exhibit worldwide distribution and are a constant threat, not only for public health but also for wildlife, domestic animals, and even plants. To study disease pathogenesis and to develop efficient and safe therapies, the use of an appropriate animal model is a critical concern. Adult mice with gene knockouts of the interferon α/β (IFN-α/β) receptor (IFNAR(−/−)) have been described as a model of arbovirus infections. Studies with the natural hosts of these viruses are limited by financial and ethical issues, and in some cases, the need to have facilities with a biosafety level 3 with sufficient space to accommodate large animals. Moreover, the number of animals in the experiments must provide results with statistical significance. Recent advances in animal models in the last decade among other gaps in knowledge have contributed to the better understanding of arbovirus infections. A tremendous advantage of the IFNAR(−/−) mouse model is the availability of a wide variety of reagents that can be used to study many aspects of the immune response to the virus. Although extrapolation of findings in mice to natural hosts must be done with care due to differences in the biology between mouse and humans, experimental infections of IFNAR(−/−) mice with several studied arboviruses closely mimics hallmarks of these viruses in their natural host. Therefore, IFNAR(−/−) mice are a good model to facilitate studies on arbovirus transmission, pathogenesis, virulence, and the protective efficacy of new vaccines. In this review article, the most important arboviruses that have been studied using the IFNAR(−/−) mouse model will be reviewed.

29 June 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
SUSergio Utrilla
Sergio Utrilla
LJLuis Jimenez-Cabello
Luis Jimenez-Cabello
RARuymán Alonso-Ravelo
Ruymán Alonso-Ravelo
ECEva Calvo-Pinilla
Eva Calvo-Pinilla
AMAlejandro Marin-Lopez
Alejandro Marin-Lopez
JOJavier Ortego
Javier Ortego
The sequence of non-structural protein NS1 of bluetongue virus (BTV), which contains immunodominant CD8+ T cell epitopes, is highly conserved among BTV serotypes, and has therefore become a major tool in the development of a universal BTV vaccine. In this work, we have engineered multiserotype BTV vaccine candidates based on recombinant chimpanzee adenovirus (ChAdOx1) and modified vaccinia virus Ankara (MVA) vectors expressing the NS1 protein of BTV-4 or its truncated form NS1-Nt. A single dose of ChAdOx1-NS1 or ChAdOx1-NS1-Nt induced a moderate CD8+ T cell response and protected IFNAR(-/-) mice against a lethal dose of BTV-4/MOR09, a reassortant strain between BTV-1 and BTV-4, although the animals showed low viremia after infection. Furthermore, IFNAR(-/-) mice immunized with a single dose of ChAdOx1-NS1 were protected after challenge with a lethal dose of BTV-8 in absence of viremia nor clinical signs. Additionally, the heterologous prime-boost ChAdOx1/MVA expressing NS1 or NS1-Nt elicited a robust NS1 specific CD8+ T cell response and protected the animals against BTV-4/MOR09 even 16 weeks after immunization, with undetectable levels of viremia at any time after challenge. Subsequently, the best immunization strategy based on ChAdOx1/MVA-NS1 was assayed in sheep. Non-immunized animals presented fever and viremia levels up to 104 PFU/mL after infection. In contrast, although viremia was detected in immunized sheep, the level of virus in blood was 100 times lower than in non-immunized animals in absence of clinical signs.

25 December 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
LJLuis Jimenez-Cabello
Luis Jimenez-Cabello
SUSergio Utrilla-Trigo
Sergio Utrilla-Trigo
ECEva Calvo-Pinilla
Eva Calvo-Pinilla
SFSandra Moreno Fernández
Sandra Moreno Fernández
ANAITOR NOGALES
AITOR NOGALES
AMAlejandro Marin-Lopez
Alejandro Marin-Lopez
Bluetongue virus (BTV), the prototype member of the genus Orbivirus (family Reoviridae), is the causative agent of an important livestock disease, bluetongue (BT), which is transmitted via biting midges of the genus Culicoides. To date, up to 29 serotypes of BTV have been described, which are classified as classical (BTV 1–24) or atypical (serotypes 25–27), and its distribution has been expanding since 1998, with important outbreaks in the Mediterranean Basin and devastating incursions in Northern and Western Europe. Classical vaccine approaches, such as live-attenuated and inactivated vaccines, have been used as prophylactic measures to control BT through the years. However, these vaccine approaches fail to address important matters like vaccine safety profile, effectiveness, induction of a cross-protective immune response among serotypes, and implementation of a DIVA (differentiation of infected from vaccinated animals) strategy. In this context, a wide range of recombinant vaccine prototypes against BTV, ranging from subunit vaccines to recombinant viral vector vaccines, have been investigated. This article offers a comprehensive outline of the live viral vectors used against BTV.

1 October 2014 in Antiviral Research
Verified
Journal Article
Closed access
AMAlejandro Marin-Lopez
Alejandro Marin-Lopez
IOIria Otero-Romero
Iria Otero-Romero
FPFrancisco de la Poza
Francisco de la Poza
RMRebeca Menaya-Vargas
Rebeca Menaya-Vargas
ECEva Calvo-Pinilla
Eva Calvo-Pinilla
JOJavier Ortego
Javier Ortego